| Excerpt | Reference |
|---|
| "Idiopathic pulmonary fibrosis is a fatal disorder that starts as an alveolitis and progresses to interstitial fibrosis." | ( Crystal, RG; Fulmer, JD; Line, BR; Moss, ML; Reynolds, HY; Roberts, WC, 1976) |
| "Idiopathic pulmonary fibrosis is an immunologically mediated pulmonary disorder in which activated alveolar macrophages (AM) and neutrophils play cardinal roles in the pathogenesis of the inflammatory lung lesion." | ( Kunkel, SL; Lynch, JP; Rolfe, MW; Standiford, TJ; Strieter, RM, 1992) |
| "The pathogenesis of pulmonary fibrosis is not well understood." | ( Greenberg, AH; Khalil, N, 1991) |
| "Idiopathic pulmonary fibrosis is an inexorably fatal disorder characterized by connective tissue deposition within the terminal air spaces resulting in loss of lung function and eventual respiratory failure." | ( Broekelmann, TJ; Colby, TV; Limper, AH; McDonald, JA, 1991) |
| "Idiopathic pulmonary fibrosis is one of the few nonembolic diseases producing a pulmonary ventilation-perfusion mismatch." | ( Almagro, UA; Collier, BD; Hellman, RS; Isitman, AT; Krasnow, AZ; Mewissen, MW; Pochis, WT, 1990) |
| "Idiopathic pulmonary fibrosis is characterized by an inflammation of the walls of the respiratory airspaces that proceed to fibrotic alveolar derangement." | ( Bernaudin, JF; Bignon, J; Brochard, P; de Cremoux, H; Laurent, P, 1990) |
| "Interstitial pulmonary fibrosis is characterized by an abnormal accumulation of fibroblasts with a resultant increase in lung collagen content." | ( Lindenschmidt, RC; Sendelbach, LE; Witschi, HP, 1985) |
| "Interstitial pulmonary fibrosis is a serious complication of inflammatory muscle disease associated with significant morbidity and mortality." | ( al-Janadi, M; Karsh, J; Smith, CD, 1989) |
| "The severity of pulmonary fibrosis is not associated with rheumatologic symptoms or the duration of the associated RA, nor is there any clear relation to the extraarticular features of RA or serologic findings." | ( Roschmann, RA; Rothenberg, RJ, 1987) |
| "Interstitial pulmonary fibrosis is described in a 26-year-old woman with malignant lymphoma after prolonged intake of cyclophosphamide." | ( Abdel Karim, FW; Allam, C; Ayash, RE; Salem, PA, 1983) |
| "Bleomycin-induced pulmonary fibrosis is associated with increased lung transforming growth factor-beta (TGF-beta) gene expression, but cellular localization of the source of this expression has not been unequivocally established." | ( Flanders, KC; Phan, SH; Zhang, K, 1995) |
| "Pre-existing pulmonary fibrosis is an independent risk factor for accelerated annual decline of FEV1, even when mild and stable." | ( Nakadate, T, 1995) |
| "Interstitial pulmonary fibrosis is characterized by increased production of connective tissue components, including collagen and elastin." | ( Agarwal, A; Goldstein, RH; Lucey, EC; Ngo, HQ; Smith, BD; Snider, GL, 1996) |
| "The prognosis of pulmonary fibrosis is poor and current therapies inadequate." | ( Coker, RK; Laurent, GJ, 1997) |
| "Cryptogenic fibrosing alveolitis is an interstitial lung disease of unknown etiology." | ( Britton, J; Cooper, M; Hubbard, R; Johnston, I; Smith, C; Venn, A, 1998) |
| "Cryptogenic fibrosing alveolitis is increasingly common, and often affects elderly males." | ( Egan, JJ; Hasleton, PS, 1998) |
| "The pathogenesis of pulmonary fibrosis is not well defined and the prognosis is poor, highlighting the need for good animal models to elucidate the cellular and molecular events that lead to pulmonary fibrosis." | ( Christensen, PJ; Goodman, RE; Moore, B; Pastoriza, L; Toews, GB, 1999) |
| "Bleomycin-induced pulmonary fibrosis is known to be associated with the increased activity of two gelatinases, matrix metalloproteinase (MMP)-2 and MMP-9, in bronchoalveolar lavage (BAL)." | ( Boichot, E; Caulet-Maugendre, S; Corbel, M; Germain, N; Lagente, V; Molet, S, 2001) |
| "Idiopathic pulmonary fibrosis is typically seen in older individuals." | ( Aggarwal, AN; Jindal, SK; Sharma, CP; Vashisht, K, 2002) |
| "Interstitial pulmonary fibrosis is a recognized complication of DM, often correlated with antisynthetase enzymes, such as anti-Jo-1." | ( Cohen, JB; Costner, MI; High, WA; Murphy, BA, 2003) |
| "As pulmonary fibrosis is not spontaneously observed in ep mice, we hypothesized that external stimuli are necessary for the genetic predisposition of its development." | ( Fukuchi, Y; Hosokawa, Y; Ishidoh, K; Kominami, E; Kumasaka, T; Mitani, K; Yoshioka, Y, 2004) |
| "The pathogenesis of pulmonary fibrosis is thought to involve alveolar epithelial injury that, when successfully repaired, can limit subsequent scarring." | ( Christensen, PJ; Du, M; Hansen, JM; Hanson, KE; Lazar, MH; Simon, RH; Sisson, TH; Subbotina, NM; White, ES; Yu, B, 2004) |
| "Idiopathic pulmonary fibrosis is an incurable fibrosing disorder that progresses relentlessly to respiratory failure." | ( Alber, S; Choi, AM; Fattman, CL; Greenhill, S; Morse, D; Oury, TD; Song, R; Zhou, Z, 2005) |
| "Idiopathic pulmonary fibrosis is characterised by the presence of active eosinophilic airway inflammation raising the possibility that airway inflammation may contribute to symptoms such as cough." | ( Birring, SS; Bradding, P; Brightling, CE; Hargadon, B; McKenna, S; Parker, D; Pavord, ID, 2005) |
| "Idiopathic pulmonary fibrosis is a chronic progressive disorder with a poor prognosis." | ( Behr, J; Buhl, R; Capron, F; Corvasce, G; Costabel, U; De Vuyst, P; Dekhuijzen, R; Demedts, M; Flower, CD; Jansen, HM; Lankhorst, I; Laurent, F; MacNee, W; Montanari, M; Nicholson, AG; Petruzzelli, S; Rodriguez-Becerra, E; Sardina, M; Thomeer, M; van den Bosch, JM; Verbeken, EK; Verschakelen, J; Wallaert, B, 2005) |
| "The mechanisms of pulmonary fibrosis are complex, and several hypotheses have been put forward to explain how fibrosis develops." | ( Belperio, JA; Keane, MP; Strieter, RM, 2005) |
| "Idiopathic pulmonary fibrosis is the most common form of the interstitial lung diseases and is characterized by chronic progressive pulmonary parenchymal fibrosis." | ( Allen, J; Baran, CP; Bhatt, N; Magro, C; Marsh, CB, 2006) |
| "Idiopathic pulmonary fibrosis is a chronic diffuse lung disease of unknown cause, and a risk factor for increasing morbidity and mortality after lung resection." | ( Ahiskali, R; Bostanci, K; Kodalli, N; Ozyurtkan, MO; Yüksel, M, 2006) |
| "Idiopathic pulmonary fibrosis is a devastating disorder for which there is no effective treatment." | ( Dohi, M; Miyazaki, J; Nakagome, K; Okunishi, K; Tanaka, R; Yamamoto, K, 2006) |
| "Idiopathic pulmonary fibrosis is a fatal disease with a variable rate of progression." | ( Andrei, AC; Colby, TV; Flaherty, KR; Fraley, C; Gross, BH; Kazerooni, EA; Lama, V; Martinez, FJ; Murray, S; Toews, GB; Travis, WD, 2006) |
| "Human pulmonary fibrosis is characterized by alveolar epithelial cell injury, areas of type II cell hyperplasia, accumulation of fibroblasts and myofibroblasts, and the deposition of extracellular matrix proteins." | ( Hogaboam, CM; Moore, BB, 2008) |
| "Indeed, pulmonary fibrosis is a major cause of death in SSc." | ( Abraham, DJ; Black, CM; Bou-Gharios, G; Denton, CP; du Bois, RM; Kennedy, L; Leask, A; Renzoni, EA; Shi-wen, X, 2007) |
| "Idiopathic pulmonary fibrosis is a progressive disease with high mortality." | ( Christensen, PJ; Fields, WB; McMillan, TR; Moore, BB; Toews, GB; van Dyk, LF; Vannella, KM; Weinberg, JB, 2008) |
| "Idiopathic pulmonary fibrosis is a lethal parenchymal lung disease characterized by denudation of the lung epithelium, fibroblast proliferation, and collagen deposition." | ( Lathrop, KL; Ray, A; Ray, P; Ray, R; Rose, JL; Shukla, MN, 2009) |
| "IPF (idiopathic pulmonary fibrosis) is a chronic progressive disease of unknown aetiology without effective treatment." | ( Goodwin, A; Jenkins, G, 2009) |
| "Idiopathic pulmonary fibrosis is a chronic progressive lung disease with poor outcome and no effective treatment to date." | ( Balduzzi, S; Cerri, S; D'Amico, R; Del Giovane, C; Luppi, F; Richeldi, L; Spagnolo, P; Walters, EH, 2010) |
| "Idiopathic pulmonary fibrosis is the most lethal diffuse fibrosing lung disease, and is characterized by the deposition of extracellular matrix." | ( Hasegawa, Y; Hashimoto, N; Hayashi, Y; Imaizumi, K; Kawabe, T; Matsushima, M; Nakamura, T; Shibasaki, M; Shimokata, K, 2011) |
| "Idiopathic pulmonary fibrosis is regarded as a lethal chronic disease accompanied with excessive collagen disposition." | ( Chen, L; Chen, Z; Luo, Y; Ma, L; Ma, Y; Qi, B; Wang, G; Wei, X; Wei, Y; Zheng, H, 2011) |
| "Idiopathic pulmonary fibrosis is a devastating disease characterized by a progressive, irreversible, and ultimately lethal form of lung fibrosis." | ( Cesta, MF; Gwinn, WM; Kapita, MC; Martin, WJ; Wang, PM, 2011) |
| "Idiopathic pulmonary fibrosis is the most prevalent chronic fibrosing lung disease." | ( El-Aidy, Ael-R; Ewais, MM; Samah, M; Tawfik, MK, 2012) |
| "Idiopathic pulmonary fibrosis is a chronic, irreversible and debilitating lung disease showing fibroblast/myofibroblast expansion and excessive deposition of extracellular matrix in the interstitium leading to breathing difficulty." | ( Chan, MH; Che, CT; Chen, M; Cheung, FW; Hui, PK; Ip, SP; Ling, YH; Liu, WK, 2012) |
| "Idiopathic pulmonary fibrosis is a rare disorder due to progressive, widespread fibrotic damage of the lung parenchyma." | ( , 2013) |
| "Idiopathic pulmonary fibrosis is a progressive and chronic lung disease of unknown cause." | ( Kim, S; Lim, JH; Woo, CH, 2013) |
| "Idiopathic pulmonary fibrosis is a progressive and lethal disease, characterized by loss of lung elasticity and alveolar surface area, secondary to alveolar epithelial cell injury, reactive inflammation, proliferation of fibroblasts, and deposition of extracellular matrix." | ( Accart, N; Beckmann, N; Cannet, C; Dunbar, A; Egger, C; Gérard, C; Jarai, G; Jarman, E; Piaia, A; Schmid, HA; Tigani, B; Vidotto, N, 2014) |
| "Idiopathic pulmonary fibrosis is thought to involve lung injury caused by reactive oxygen species (ROS), which in turn is followed by abnormal fibrosis." | ( Asano, T; Azuma, A; Kurotsu, S; Mizushima, T; Niino, T; Sugizaki, T; Suzuki, H; Tanaka, K, 2014) |
| "Idiopathic pulmonary fibrosis is a progressive fatal lung disease characterized by excessive collagen deposition, with no effective treatments." | ( Chilakapati, DR; Chilakapati, SR; Manikonda, PK; Serasanambati, M; Watson, RR, 2014) |
| "Idiopathic pulmonary fibrosis is characterized by a progressive and irreversible respiratory failure." | ( Bondue, B; De Vuyst, P; Doumont, G; Egrise, D; Goldman, S; Huaux, F; Lacroix, S; Parmentier, M; Rorive, S; Sauvage, S; Sherer, F; Van Simaeys, G; Vosters, O; Yakoub, Y, 2015) |
| "Idiopathic pulmonary fibrosis is a chronic pulmonary disease that is characterized by formation of scar tissue in lungs." | ( Abdullah, M; Ho, CC; Koh, RY; Lim, CL; Seow, HF; Uhal, BD; Vidyadaran, S, 2015) |
| "Idiopathic pulmonary fibrosis is a chronic and progressive fibrotic lung disorder with unknown etiology and a high mortality rate." | ( Feng, Z; Gao, L; He, H; Lin, H; Tang, H; Wu, T; Wu, Y, 2015) |
| "Idiopathic pulmonary fibrosis is the most devastating diffuse fibrosing lung disease of unknown aetiology." | ( Borensztajn, K; Crestani, B; Daalhuisen, J; Lin, C; Spek, CA; ten Brink, M; van der Poll, T; von der Thüsen, J, 2015) |
| "Radiation-induced pulmonary fibrosis is a common disease and has a poor prognosis owing to the progressive breakdown of gas exchange regions in the lung." | ( Chang, PY; Cui, S; Dong, LH; Jiang, X; Jiang, YY; Liu, F; Liu, YJ; Qu, C; Qu, YQ; Xia, CC, 2015) |
| "The pulmonary fibrosis is a common feature of several diseases and may be induced by inflammatory disorders following inhalation of organic and inorganic dusts (e." | ( Riccò, M, 2015) |
| "Idiopathic pulmonary fibrosis is a lethal lung disease that is characterized by the accumulation of extracellular matrix and a change in lung structure." | ( Chono, S; Tada, H; Togami, K, 2016) |
| "Radiation-induced pulmonary fibrosis is a severe side effect of thoracic irradiation, but its pathogenesis remains poorly understood and no effective treatment is available." | ( Blackburn, MR; Cappuccini, F; Chen, NY; de Leve, S; Eldh, T; Fischer, U; Gau, E; Jendrossek, V; Karmouty-Quintana, H; Kasper, M; Klein, D; Meyer, AV; Ritchey, JW; Stuschke, M; Thompson, LF; Westendorf, AM; Wirsdörfer, F, 2016) |
| "IR-induced pulmonary fibrosis is one of the most severe late complications of radiotherapy for lung cancer." | ( Chen, C; Han, D; Hong, J; Ma, J; Okunieff, P; Yang, S; Zhang, L; Zhang, M; Zhang, SB; Zhang, Z, 2016) |
| "Idiopathic pulmonary fibrosis is a progressive, degenerative and almost irreversible disease." | ( He, S; Hu, C; Meng, Q; Ouyang, Z; Shen, Y; Sun, Y; Wang, X; Wu, X; Xu, Q; You, Q, 2016) |
| "Idiopathic pulmonary fibrosis is a devastating disease." | ( Bianchi, A; Crémillieux, Y; Lux, F; Raffard, G; Sanchez, S; Tassali, N; Tillement, O, 2016) |
| "Idiopathic pulmonary fibrosis is a severe disease characterized by excessive myofibroblast proliferation, extracellular matrix and fibrils deposition, remodelling of lung parenchyma and pulmonary insufficiency." | ( Boccalini, G; Calosi, L; Durante, M; Lanzi, C; Lucarini, L; Mannaioni, G; Masini, E; Moroni, F; Pini, A, 2017) |
| "Idiopathic pulmonary fibrosis is known as a life-threatening disease with high mortality and limited therapeutic strategies." | ( Dong, SH; Han, ZD; Liu, YW; Tan, HZ; Wei, F, 2017) |
| "Progressive pulmonary fibrosis is the most characteristic feature of subacute PQ poisoning." | ( Cao, Y; Li, T; Wang, N; Xin, S; Yang, X, 2017) |
| "Radiation-induced pulmonary fibrosis is a severe complication of patients treated with thoracic irradiation." | ( Chu, SG; Doyle-Eisele, M; El-Chemaly, S; Liu, X; McDonald, J; Patino-Jaramillo, NG; Perrella, MA; Rosas, IO; Tsoyi, K; Villalba, J; Wilder, J, 2018) |
| "Idiopathic Pulmonary fibrosis is a disease with high morbidity and mortality." | ( Cao, B; Chen, H; Chen, Y; Li, W; Liu, B; Liu, T; Liu, Y; Rong, Y, 2018) |
| "Drug-induced pulmonary fibrosis is associated with pulmonary hypoplasia." | ( Azuma, E; Hirayama, M; Ito, T; Iwamoto, S; Koyama, S, 2018) |
| "Diffuse pulmonary fibrosis is the major pathological change of pneumoconiosis, and its mechanism is still unclear." | ( Che, S; Liu, K; Liu, Z; Wang, H; Wang, K; Yang, H; Zhang, N; Zhou, C, 2019) |
| "Silica-induced pulmonary fibrosis is a kind of worldwide occupational disease, and there is no effective treatment at present." | ( Ji, X; Li, P; Li, Y; Liu, Y; Ni, C; Pan, H; Xu, Q; Yao, W; Yuan, J, 2019) |
| "Idiopathic pulmonary fibrosis is characterized by loss of lung epithelial cells and inexorable progression of fibrosis with no effective and approved treatments." | ( Chen, M; Dong, M; Gao, Y; Han, L; Jin, F; Li, W; Lin, H; Shi, Y; Zhou, Y; Zuo, W, 2019) |
| "Idiopathic pulmonary fibrosis is characterized by aberrant fibroblast activation and excessive collagen deposition that may eventually lead to organ dysfunction." | ( Cassali, GD; Galvão, I; Kraemer, L; Melo, EM; Rago, F; Russo, RC; Santos, RAS; Teixeira, MM, 2019) |
| "Early pulmonary fibrosis is the leading cause of poor prognosis in patients with acute respiratory distress syndrome (ARDS)." | ( Cao, Y; Guo, Y; Li, Y; Liu, Y; Ping, F; Shang, J; Yao, S; Yuan, Z, 2019) |
| "Idiopathic pulmonary fibrosis is a lung disease with limited therapeutic options that is characterized by pathological fibroblast activation and aberrant lung remodeling with scar formation." | ( Bieler, M; Black, KE; Grasberger, P; Hariri, LP; Lin, Y; Medoff, BD; Nichols, R; Nicklin, P; Pantano, L; Probst, CK; Pronzati, G; Santos, DM; Seither, P; Spinney, JJ; Tager, AM; Wyatt, D, 2020) |
| "Idiopathic pulmonary fibrosis is a progressive-fibrosing lung disease with high mortality and limited therapy, which characterized by myofibroblasts proliferation and extracellular matrix deposition." | ( Bi, Z; Deng, R; Gao, S; Li, H; Li, S; Li, X; Liang, L; Lin, J; Liu, M; Luan, J; Ma, L; Miao, Y; Wang, M; Wang, Y; Yang, C; Yu, H; Zhou, H, 2020) |
| "Idiopathic pulmonary fibrosis is a debilitating lung disease." | ( Liu, Y; Qi, Y, 2020) |
| "The evolution to pulmonary fibrosis is frequent in older males and patients with comorbidities and bone marrow involvement." | ( Balzarini, L; Ferrozzi, F; Mancini, C; Marvisi, M; Ramponi, S; Uccelli, M, 2020) |
| "Idiopathic pulmonary fibrosis is a chronic, progressive, fibrotic disease." | ( Feng, F; Gu, C; Han, D; He, H; Hrovat, J; Li, J; Peng, W; Shan, J; Wang, Z; Wu, Q; Xu, Y; Yang, P; Zhou, X, 2021) |
| "The development of pulmonary fibrosis is a rare complication of the novel coronavirus disease 2019 (COVID-19)." | ( Alamoudi, A; Alnami, A; Badedi, M; Farghaly, S; Ibrahim, R; Muhajir, A; Sadhan, MH, 2022) |
| "PQ-induced pulmonary fibrosis is the main reason for respiratory failure and death." | ( Gong, N; Huang, C; Jiang, J; Xue, X, 2022) |
| "Idiopathic pulmonary fibrosis is a terminal lung ailment that shares several pathological and genetic mechanisms with severe COVID-19." | ( Arafa, EA; Hussein, RM; Mohamed, WR; Raheem, SA, 2023) |
| "Diffuse interstitial pulmonary fibrosis is sometimes found in the lungs of this pneumoconiosis." | ( Akira, M; Suganuma, N, 2023) |
| "The incidence of pulmonary fibrosis is on the rise, and existing treatments have limited efficacy in improving patient survival." | ( Han, X; Wang, S; Wu, W, 2023) |
| "Idiopathic pulmonary fibrosis is a chronic and highly lethal lung disease that largely results from oxidative stress; however, effective antioxidant therapy by targeting oxidative stress pathogenesis is still lacking." | ( Chen, C; He, W; Huang, Y; Jia, H; Kotha, S; Liu, Q; Mao, X; Ren, Y; Tong, Y; Wang, L; Yuan, H; Zheng, Z, 2023) |
| Excerpt | Reference |
|---|
| "A model for pulmonary fibrosis in the rat has been developed using intratracheal administration of bleomycin." | ( Jack, RM; McCormick, JR; McReynolds, RA; Thrall, RS; Ward, PA, 1979) |
| "Acexamic acid is currently used to avoid pulmonary fibrosis in patients treated with bleomycim." | ( Barale, F; Berthout, P; Boillot, A; Bourgeois, F; Daoudal, P, 1979) |
| "A case of fatal pulmonary fibrosis and atypical epithelial proliferation (AEP) in a patient with multiple myeloma treated with melphalan is presented." | ( Dickman, PS; Feldman, PS; Taetle, R, 1978) |
| "Ten patients developed pulmonary fibrosis after bischloroethylnitrosourea (BCNU) therapy for malignancy." | ( Bartolucci, AA; Durant, JR; Langford, KH; Murad, TM; Norgard, MJ, 1979) |
| "A case is reported of a child with fatal pulmonary fibrosis following BCNU therapy." | ( Bailey, CC; Jones, PH; Marsden, HB, 1978) |
| "Long-term therapy with BCNU may cause pulmonary fibrosis, as has been seen with other cytotoxic drugs." | ( Crittenden, D; Haut, A; Tranum, BL, 1977) |
| "Intersitial pneumonia and pulmonary fibrosis developed in a 72-year-old man during therapy with cyclophosphamide, vincristine, and prednisone." | ( Patel, AR; Rao, KP; Rhee, HL; Sassoon, H; Shah, PC, 1976) |
| "A model of pulmonary fibrosis in rat has been developed using intratracheal administration of bleomycin (BLM) A5 (5mg/kg)." | ( Wang, XZ, 1992) |
| "The simultaneous occurrence of pulmonary fibrosis and chronic active hepatitis in a patient undergoing long-term nitrofurantoin therapy is reported." | ( Korlipara, P; Peleman, R; Reinhart, E; Reinhart, HH, 1992) |
| "A diffuse interstitial pulmonary fibrosis associated with an idiopathic hepatic cirrhosis occurred in a 79 years old man treated during five years with cyclothiazide and triamterene for a mild systemic hypertension." | ( Chabot, F; Delorme, N; Gerard, H; Kheir, A; Lesur, O; Polu, JM, 1992) |
| "In the present paper, we evidenced that pulmonary fibrosis could be induced in genetically mast cell-deficient WBB6F1-W/Wv mice as well as WBB6F1-(+/+) mice having mast cells normally by the treatment with bleomycin (BLM, 5 mg/kg, i." | ( Kawada, K; Koda, A; Mori, H; Sakamoto, O; Uesugi, Y; Zhang, P, 1991) |
| "Histological examination revealed fibrosing alveolitis in the BLM-treated group which was markedly suppressed in the combination group." | ( Burkhardt, A; Mall, G; Otto, HF; Siemens, I; Zimmermann, P, 1991) |
| "A 54 year old, postmenopause female with pulmonary fibrosis on steroid therapy is studied for lumbar and sacral pain." | ( Alvarado, A; Guzmán, L; Maluje, V, 1991) |
| "In order to prevent pulmonary fibrosis, we employed radiotherapy of both lungs in a 23-year-old patient with severe paraquat poisoning; however, it failed to prevent the fatal outcome." | ( Baer, F; Baldamus, CA; Curtius, JM; Eidt, S; Franzen, D; Heitz, W; Höpp, HW; Käferstein, H; Mecking, H; Wassermann, K, 1991) |
| "Following this treatment, symptoms of fibrosing alveolitis developed which were resistant to treatment and led to death." | ( Herrmann, G; Hübner, K, 1988) |
| "Amiodarone-induced bilateral diffuse pulmonary fibrosis developed in a 47-year-old woman with idiopathic hypertrophic subvalvular aortic stenosis who had been treated with amiodarone (Cordarex), 300 mg daily for about 18 months." | ( Esinger, W; Gröger, C; Hertrich, F; Köhler, G; Leinberger, H; Raute-Kreinsen, U; Schleiffer, T, 1988) |
| "He died 24 days later from progressive pulmonary fibrosis (Paraquat lung) despite intensive therapy to combat the toxicity of the poison to lung, kidney, and liver." | ( Hughes, JT, 1988) |
| "Diffuse interstitial lung disease and pulmonary fibrosis occurred after the use of vindesine and radiation therapy in a patient with squamous cell carcinoma of the lung." | ( Bott, SJ; Prince-Fiocco, MA; Stewart, FM, 1986) |
| "Ten patients with fibrosing alveolitis were treated in a simple random design initially with either a high dose of methylprednisolone (5 patients) or a conventional dose of prednisolone (5 patients) followed by a maintenance dose of 30 mg prednisolone daily." | ( Bergmann, A; Frøland, SS; Gulsvik, A; Kjelsberg, F; Rootwelt, K; Vale, JR, 1986) |
| "Idiopathic pulmonary fibrosis was diagnosed and aggressive treatment with methylprednisolone sodium succinate and nutritional support was initiated." | ( Ashbaugh, DG; Maier, RV, 1985) |
| "Patients with idiopathic pulmonary fibrosis (IPF) are often cigarette smokers and are often being treated with corticosteroids at the time of bronchoalveolar lavage." | ( Cherniack, RM; Christopher, KL; King, TE; Schwarz, MI; Stanford, RE; Waldron, JA; Watters, LC; Willcox, ML, 1986) |
| "We studied 12 patients with pulmonary fibrosis treated with D-Penicillamine in an attempt to regulate the collagen metabolism that is seriously affected in this group of patients." | ( Chapela, R; Selman, M; Zúñiga, G, 1986) |
| "A case of pneumonitis and pulmonary fibrosis occurring during long term treatment with amiodarone hydrochloride is described." | ( Cosentino, G; De Vuono, T; Pesola, A; Vercillo, C, 1985) |
| "Pharmacologic treatment of pulmonary fibrosis has been limited to the use of corticosteroids occasionally combined with other immunosuppressive agents." | ( Evans, JN; Kelley, J; Newman, RA, 1980) |
| "Six of the seven patients died of pulmonary fibrosis in spite of prednisone treatment." | ( Eguchi, K; Koketsu, H; Nakajima, T; Niitani, H; Saijo, N; Shibuya, M; Shimabukuro, Z; Shimizu, E; Shinkai, T; Tominaga, K, 1983) |
| "We report a patient with fibrosing alveolitis associated with amiodarone therapy." | ( Butland, RJ; Millard, FJ, 1984) |
| "She developed progressive, pulmonary fibrosis as a consequence of chemotherapy, which lead to her death." | ( Révész, T; Somló, P, 1984) |
| "Four cases of interstitial pulmonary fibrosis associated with nitrofurantoin therapy are analysed along with 45 other reported cases of this disease in order to review the presenting features and outcome and to determine the role of steroid therapy." | ( Robinson, BW, 1983) |
| "Two cases of histologically proven pulmonary fibrosis resulting from amiodarone therapy but responding to corticosteroids are reported." | ( Clarke, SW; Evans, TR; Ormerod, LP; Quyyumi, AA; Ward, RL, 1983) |
| "In a model of paraquat-induced pulmonary fibrosis using the cynomolgus monkey, the administration of paraquat (10 mg/kg/wk subcutaneously for 2 consecutive wk) was followed by an alveolitis comprised of neutrophils and macrophages in the exposed animals as evaluated by lung morphologic examination and bronchoalveolar lavage." | ( Bitterman, PB; Crystal, RG; Ferrans, VJ; Fukuda, Y; Rennard, SI; Schoenberger, CI, 1984) |
| "In one case without any treatment pulmonary fibrosis developed." | ( Hartjen, A; Schicht, R; Sill, V, 1982) |
| "Three patients who developed pulmonary fibrosis following prolonged treatment with nitrofurantoin for chronic urinary tract infections are presented." | ( Benatar, SR; Maze, SS; Sandler, M; Willcox, PA, 1982) |
| "A minority of patients with cryptogenic fibrosing alveolitis (idiopathic pulmonary fibrosis) respond to treatment with corticosteroids." | ( Haslam, PL; Rudd, RM; Turner-Warwick, M, 1981) |
| "We conclude that acute pulmonary fibrosis caused by exposure of rats to high levels of inspired ozone can be partially or completely prevented, depending on the severity of the insult, by simultaneous administration of high levels of the anti-inflammatory steroid methylprednisolone." | ( Hesterberg, TW; Last, JA, 1981) |
| "We treated two types of experimental pulmonary fibrosis elicited in mice by the intratracheal instillation of bleomycin or silica with monoclonal antibodies (mAbs) specific for the leukocytic integrins CD-11a or CD-11b." | ( Grau, GE; Piguet, PF; Rosen, H; Vesin, C, 1993) |
| "Of the eight patients who died of pulmonary fibrosis, the median age at treatment was 2." | ( Gattamaneni, HR; Kalra, S; O'Driscoll, BR; Woodcock, AA, 1995) |
| "Idiopathic pulmonary fibrosis (IPF) is a poorly understood interstitial disease that usually proves refractory to therapy and results in irreversible tissue scarring and pulmonary dysfunction." | ( Arenberg, DA; Burdick, MD; Hampton, JN; Kunkel, SL; Lynch, JP; Martinez, FJ; Rolfe, MW; Smith, DR; Standiford, TJ; Wilke, CA, 1995) |
| "This unique animal model of progressive pulmonary fibrosis resembles the final stages of human idiopathic pulmonary fibrosis and should facilitate studying underlying mechanisms and potential therapy of progressive pulmonary fibrosis." | ( Gelzleichter, TR; Last, JA; Pinkerton, KE; Walker, RM; Witschi, H, 1993) |
| "A diffuse interstitial pulmonary fibrosis occurred in a 74-year-old woman treated for ten years with labetalol for systemic hypertension." | ( Chabot, F; Delorme, N; Kheir, A; Polu, JM, 1996) |
| "In pulmonary diseases such as idiopathic pulmonary fibrosis or following HIV infection, GSH aerosol therapy not only normalized deficient pretherapy GSH levels in the lung, but was capable of favorably influencing cellular events such as oxidant release by pulmonary inflammatory cells." | ( Buhl, R; Meyer, A; Vogelmeier, C, 1996) |
| "To examine this hypothesis, pulmonary fibrosis was induced in mice by endotracheal bleomycin treatment, and separate groups of animals were also treated with either anti-TNF-alpha Ab or control serum." | ( Gharaee-Kermani, M; McGarry, B; Phan, SH; Remick, D; Zhang, K, 1997) |
| "Therapy of idiopathic pulmonary fibrosis (IPF) is directed at 1) inhibition of alveolitis and tissue damage, and 2) inhibition of matrix deposition." | ( Entzian, P; Gerdes, J; Gerlach, C; Schlaak, M; Zabel, P, 1997) |
| "We report three patients with advanced pulmonary fibrosis in whom steroid therapy failed and that received cyclosporine in a dose of 3 to 5 mg/kg for three to five months." | ( Meneses, M; Oyarzún, M; Undurraga, A, 1997) |
| "The diagnosis of idiopathic pulmonary fibrosis can be made only after exclusion of other entities such as neoplasm, toxic treatments, collagen vascular diseases, occupational exposure or granulomatous diseases, such as sarcoidosis." | ( Nicod, LP, 1998) |
| "Idiopathic pulmonary fibrosis (IPF) is associated with significant morbidity and mortality despite aggressive therapy." | ( Cascade, PN; Flint, A; Gay, SE; Gross, BH; Hyzy, R; Kazerooni, EA; Lynch, JP; Martinez, FJ; Popovich, J; Schork, MA; Spizarny, DL; Toews, GB; Whyte, RI, 1998) |
| "Idiopathic pulmonary fibrosis (cryptogenic fibrosing alveolitis) is a disorder with a very poor prognosis for patients who do not respond to therapy with corticosteroids alone or in combination with immunosuppressive drugs, e." | ( Demedts, M; Lerut, T; Sels, F; Van Raemdonck, D; Verbeken, EK; Verleden, GM, 1998) |
| "We report a case of pulmonary fibrosis in an infant receiving amiodarone for treatment of intractable atrioventricular reentrant tachycardia secondary to Wolff-Parkinson-White syndrome." | ( Bowers, PN; Fields, J; Nehgme, R; Rosenfeld, LE; Schwartz, D, 1998) |
| "In a bleomycin-induced pulmonary fibrosis model in rats, treatment with SB 239063 (2." | ( Adams, JL; Bochnowicz, S; Griswold, DE; Hay, DW; Lee, JC; Osborn, RR; Rieman, DJ; Romanic, AM; Underwood, DC; Webb, EF, 2000) |
| "Bleomycin treatment in rats results in pulmonary fibrosis that is characterized by a rapid shallow breathing pattern, a decrease in quasi-static lung compliance and a blunting of the Hering-Breuer Inflation Reflex." | ( Chen, AT; Mansoor, JK; Schelegle, ES; Walby, WF, 2001) |
| "For the pulmonary fibrosis study, FG-/- mice and wildtype littermates were administered a bleomycin solution intratracheally and the disease was allowed to progress for two weeks." | ( Castellino, FJ; Cornelissen, I; Deford, ME; Feldman, M; Liang, Z; McLennan, L; Ploplis, VA; Rosen, ED; Wilberding, JA, 2001) |
| "Idiopathic pulmonary fibrosis (IPF) is a condition that has a poor prognosis, with a median survival of 4-5 years irrespective of treatment." | ( Millar, A, 2000) |
| "PIF models of bleomycin-A5-induced pulmonary fibrosis were established in rats, they were treated by Bailuda, a preparation of FGB, and the pathological changes, collagen protein level, nuclear factor kB(NF-kB) activity, transforming growth factor beta (TGF-beta) mRNA expression and protein level of the lung tissue were measured." | ( Chen, J; He, B; Liu, X, 2000) |
| "Many possible treatments for pulmonary fibrosis have been investigated, but except for some current clinical trials, none have succeeded in clinical trials." | ( Guo, LY; Jia, YX; Kamanaka, M; Ohrui, T; Okinaga, S; Sasaki, H; Takahashi, H; Wang, HD; Yamaya, M, 2002) |
| "Twenty-five days after BLM treatment, pulmonary fibrosis was assessed as hydroxyproline content in lung homogenates." | ( Arslan, SO; Coskun, A; Vural, H; Zerin, M, 2002) |
| "Sometimes the disease progresses to pulmonary fibrosis and respiratory failure despite treatment with corticosteroids." | ( Kaajan, JP; van der Drift, MA, 2002) |
| "Idiopathic pulmonary fibrosis (IPF) is an inflammatory disorder of the lungs of unknown etiology, with no effective treatment." | ( Altschuler, EL, 2001) |
| "The median time for the development of pulmonary fibrosis was 8 months in TAM-treated patients whereas it was 10 months in non-TAM-treated patients." | ( Koc, M; Polat, P; Suma, S, 2002) |
| "Rats were divided into 3 groups: pulmonary fibrosis group, PNS treated group and solu-medrol treated group." | ( Cui, S; Li, X, 2002) |
| "A patient with fibrosing alveolitis on prolonged cyclophosphamide treatment developed therapy-related MDS." | ( Au, WY; Kwong, YL; Ma, SK; Man, C; Wan, TS, 2003) |
| "To compare the effects of treatment of pulmonary fibrosis (PF) by the Chinese herbal medicines, Radix Salviae miltiorrhizae (C1), Radix Astragalus membranaceus (C2) and Caulis Tripterygium wilfordii (C3); western drugs, hydrocortisone (W1) and azathioprine (W2), and combined W2 with C3." | ( Cai, HR; Dai, LJ; Hou, J, 2004) |
| "Treatment of patients with idiopathic pulmonary fibrosis (IPF) conventionally includes corticosteroids and cytotoxic agents." | ( Brown, KK; Collard, HR; Curran-Everett, D; Douglas, WW; King, TE; Ryu, JH; Schwarz, MI, 2004) |
| "In conclusion, pulmonary fibrosis can develop early and progress rapidly after the administration of high-dose BCNU." | ( Chen, CL; Chiu, CF; Chow, KC; Liaw, YC; Shen, YC; Yeh, SP, 2004) |
| "Idiopathic pulmonary fibrosis (IPF) is a fatal disorder without an effective therapy to date." | ( Abe, S; Azuma, A; Itoh, H; Kudoh, S; Nagai, S; Nakata, K; Nukiwa, T; Ohi, M; Sato, A; Suga, M; Taguchi, Y; Tsuboi, E, 2005) |
| "Cough is a common symptom in idiopathic pulmonary fibrosis that is difficult to treat and has a major impact on quality of life." | ( Birring, SS; Bradding, P; Brightling, CE; Hargadon, B; McKenna, S; Parker, D; Pavord, ID, 2005) |
| "A 74-year-old man with idiopathic pulmonary fibrosis (IPF) developed severe dyspnea on exertion after the readministration of imatinib mesylate for chronic myeloid leukemia." | ( Bando, M; Ohno, S; Sugiyama, Y; Yamasawa, H, 2008) |
| "Finally, ganciclovir treatment prevented pulmonary fibrosis following MCMV reactivation." | ( Cook, CH; Ferguson, RM; Jewell, S; Martin, LC; Sedmak, DD; Zhang, Y, 2006) |
| "The treatment of idiopathic pulmonary fibrosis (IPF) remains controversial." | ( Nathan, SD, 2006) |
| "Idiopathic pulmonary fibrosis (IPF)/usual interstitial pneumonia is a deadly disease with no effective treatment." | ( Antoniou, KM; Bouros, D; Dimadi, M; Latsi, P; Malagari, K; Nicholson, AG; Polychronopoulos, V; Rapti, A; Trigidou, R; Tzanakis, N, 2006) |
| "Experimental pulmonary fibrosis was induced by intra-tracheal administration of BLM in anesthetized mice." | ( Huang, YH; Li, Y; Ouyang, ZG; Shang, Y; Zhen, YS, 2006) |
| "Idiopathic pulmonary fibrosis is a devastating disorder for which there is no effective treatment." | ( Dohi, M; Miyazaki, J; Nakagome, K; Okunishi, K; Tanaka, R; Yamamoto, K, 2006) |
| "The degree of pulmonary fibrosis was much greater in GATA-3-tg mice than in wild-type mice 28 days after bleomycin treatment." | ( Homma, S; Iizuka, T; Ishii, Y; Kimura, T; Kiwamoto, T; Matsuno, Y; Morishima, Y; Nomura, A; Sakamoto, T; Sekizawa, K; Takahashi, S; Yoh, K, 2006) |
| "These results indicate that PQ-induced pulmonary fibrosis does not merely terminate as cicatrices three months after the discontinuation of PQ treatment, but that dynamic functional change continues in the lung." | ( Akahori, F; Kasahara, Y; Miura, D; Satomi, Y; Tsuchiya, W, 2006) |
| "This suggests that treatment of pulmonary fibrosis in SSc with low-dose prednisolone and IV CYC followed by AZA stabilizes lung function in a subset of patients with the disease." | ( Black, CM; Denton, CP; Desai, S; du Bois, RM; Ellis, RW; Emery, P; Foley, NM; Goh, NS; Herrick, AL; Hoyles, RK; Lees, B; McHugh, NJ; Newlands, P; Pearson, SB; Roberts, C; Veale, DJ; Wells, AU; Wellsbury, J, 2006) |
| "Idiopathic pulmonary fibrosis (IPF) is a fatal disease for which no effective treatment exists." | ( Behr, J; Enke, B; Ghofrani, HA; Grimminger, F; Günther, A; Hammerl, P; Leconte, I; Markart, P; Morr, H; Roux, S; Seeger, W; Stähler, G, 2007) |
| "Bleomycin-induced pulmonary fibrosis (PF) in rats was utilized to value the treatment with valsartan, an AT1 receptor antagonist, by measurement of body weight, wet weight of the left lung, hydroxy-proline content, mRNA expression of collagen I/III, and the degree of fibrosis in lung tissues on d 21." | ( Cai, Y; Chen, FP; Gong, LK; Li, XH; Liu, LL; Qi, XM; Ren, J; Wang, H; Wu, XF; Xiao, Y; Zhang, L, 2007) |
| "Idiopathic pulmonary fibrosis (IPF) is a deadly disease, largely unresponsive to treatment with corticosteroids and immunosuppressives." | ( Antoniou, KM; Bouros, D; Koutsopoulos, A; Lambiri, I; Maltezakis, G; Plataki, M; Siafakas, NM; Tzanakis, N; Tzortzaki, EG; Zervou, MI, 2007) |
| "Treatment with paraquat alone induced pulmonary fibrosis in the entire group, while treatment with the antisense oligonucleotide alone did not produce any substantial change in lung histology." | ( Hagiwara, S; Iwasaka, H; Matsumoto, S; Noguchi, T, 2007) |
| "Imatinib alone did not ameliorate pulmonary fibrosis when treatment was started on Day 15, whereas coadministration of imatinib and EM or CAM significantly reduced the fibrogenesis via inhibition of the growth of fibroblasts in vivo." | ( Aono, Y; Azuma, M; Inayama, M; Izumi, K; Kinoshita, K; Kishi, J; Makino, H; Nishioka, Y; Ogushi, F; Shono, M; Sone, S; Uehara, H, 2007) |
| "Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal lung disease lacking effective treatment." | ( Behr, J; Brown, KK; de Andrade, JA; du Bois, RM; King, TE; Lancaster, L; Leconte, I; Raghu, G; Roux, S; Stähler, G, 2008) |
| "The worsening of pulmonary fibrosis was mainly induced by CGS27023A administration in the late phase of bleomycin-induced pulmonary fibrosis development, but not in the early phase." | ( Fujita, M; Harada, E; Ikegame, S; Inoshima, I; Kuwano, K; Nakanishi, Y; Ouchi, H; Ye, Q, 2008) |
| "Idiopathic pulmonary fibrosis (IPF) is a treatment resistant disease with poor prognosis." | ( Ask, K; Farkas, L; Farncombe, T; Froese, A; Gauldie, J; Inman, M; Kolb, MR; Labiris, R; McClelland, GB; Moeller, A, 2008) |
| "In the former 3 groups, pulmonary fibrosis was induced via intratracheal injection of bleomycin A5 (5 mg/kg), after which the rats in the perindopril and losartan groups received intragastric administration of the corresponding agents at the daily dose of 2 mg/kg and 10 m/kg, respectively." | ( Cai, SX; Cheng, YX; Li, X; Meng, Y; Tong, WC, 2008) |
| "There is no satisfactory treatment for pulmonary fibrosis, which is characterized by altered control of proliferation of mesenchymal fibroblasts and extracellular matrix production." | ( Chen, X; Hu, J; Liao, D; Mo, Z; Sun, R; Yang, Z; Zhong, N, 2008) |
| "Idiopathic pulmonary fibrosis (IPF) is a debilitating, fatal, chronic fibrosing lung disease with no known effective therapy." | ( King, TE, 2008) |
| "Bleomycin-induced pulmonary fibrosis mice were treated intraperitoneally with VEGF receptor tyrosine kinase inhibitor SU5416 at different phases after bleomycin infusion." | ( Chen, L; Feng, YL; Huang, XY; Li, WC; Li, YP; Liu, DS; Ou, XM; Wang, K; Wang, T; Wang, X; Wen, FQ; Zhang, SF, 2009) |
| "To treat pulmonary fibrosis and study its mechanisms." | ( Ding, K; Lei, FF; Wang, XX; Yao, BT; Zhao, JX, 2008) |
| "Bleomycin-induced pulmonary fibrosis mice were administered with simvastatin in different doses for 28 days." | ( Feng, YL; Huang, XY; Ou, XM; Wang, K; Wang, T; Wen, FQ; Xiao, J, 2008) |
| "Patients with idiopathic pulmonary fibrosis have a high incidence of lung cancer and a worse prognosis for clinical treatment." | ( Du, G; Han, X; Jin, L; Liang, W; Song, Z; Zhang, H, 2009) |
| "IPF (idiopathic pulmonary fibrosis) is a chronic progressive disease of unknown aetiology without effective treatment." | ( Goodwin, A; Jenkins, G, 2009) |
| "Sivelestat inhibited pulmonary fibrosis by blocking these mitochondria-mediated apoptotic pathways in bleomycin-treated rats and in elastase-treated A549 cells." | ( Kang, CM; Kim, YK; Moon, HS; Park, SH; Rhee, CK; Song, JS; Yoon, HK, 2009) |
| "The collagen content and pulmonary fibrosis were significantly attenuated by AMD3100 treatment in later stage of bleomycin injury." | ( Kang, CM; Kang, HH; Kim, KH; Kim, YK; Moon, HS; Park, SH; Song, JS; Yoon, HK, 2010) |
| "Idiopathic pulmonary fibrosis (IPF) has a poor prognosis and limited responsiveness to available treatments." | ( Amarie, OV; Dumitrascu, R; Eickelberg, O; Grimminger, F; Königshoff, M; Reiter, R; Schermuly, RT; Seeger, W; Udalov, S, 2010) |
| "Idiopathic pulmonary fibrosis is a chronic progressive lung disease with poor outcome and no effective treatment to date." | ( Balduzzi, S; Cerri, S; D'Amico, R; Del Giovane, C; Luppi, F; Richeldi, L; Spagnolo, P; Walters, EH, 2010) |
| "Here we used the bleomycin model of pulmonary fibrosis to investigate fibrotic responses in normal and ASM knockout (ASM(-/-)) mice, and in NIH3T3 fibroblasts with and without ASM siRNA treatment." | ( Dhami, R; He, X; Schuchman, EH, 2010) |
| "Idiopathic pulmonary fibrosis (IPF) is a chronic fibroproliferative pulmonary disorder for which there are currently no treatments." | ( Akbari, O; Banfalvi, A; Borok, Z; Krishnaveni, MS; Li, A; Li, C; Li, M; Lombardi, V; Minoo, P; Xing, Y; Zhou, B, 2011) |
| "Except one patient who had asymptomatic pulmonary fibrosis, chest computed tomography before chemotherapy showed no fibrotic changes." | ( Furushima, K; Ishihara, T; Katou, Y; Tanai, C; Tanaka, Y; Usui, K, 2011) |
| "There is no effective treatment for the pulmonary fibrosis except lung transplantation, but an initial trial using pirfenidone, an anti-fibrotic agent, showed promising results." | ( Bernardini, I; Cardona, H; Gahl, WA; Gochuico, BR; Hess, R; Markello, TC; O'Brien, K; Salas, J; Troendle, J; Yao, J, 2011) |
| "In this study, an established model of pulmonary fibrosis was used in which 10-12-wk-old male C57BL/6 mice were administered a single dose (1." | ( Bradbury, JA; Card, JW; Cheng, J; Dackor, RT; DeGraff, LM; Edin, ML; Ferguson, CD; Flake, GP; Garrett, RC; Lih, FB; Morgan, DL; Ramsey, RW; Tomer, KB; Travlos, GS; Voltz, JW; Zeldin, DC, 2011) |
| "He developed pulmonary fibrosis during the course of his chemotherapy, and therefore further chemotherapy was stopped." | ( Chan, AK; Choo, BA; Glaholm, J, 2011) |
| "The scores of alveolitis and pulmonary fibrosis in the groups treated with EOCR at doses of 100 and 200 mg/kg per day were significantly lower than those in the model group (Plt;0." | ( He, CC; Li, JX; Zhao, Y; Zhou, XM, 2012) |
| "Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal lung disease without beneficial therapy, except for lung transplantation." | ( Chen, L; Li, J; Li, S; Li, W; Su, X; Yan, G; Yang, X, 2012) |
| "PFD used for the treatment of pulmonary fibrosis is not so safe or well-tolerated." | ( Huang, H; Jiang, C; Liu, J; Lu, Z; Wang, Y; Xu, Z, 2012) |
| "In idiopathic pulmonary fibrosis (IPF), recent randomised, placebo-controlled trials have tested the efficacy of new therapies, and although primary end points have not been met in most, treatment effects have been observed." | ( Lota, HK; Wells, AU, 2013) |
| "In the current study, pulmonary fibrosis of rats was produced by a single oral dose of 50 mg/kg bw PQ treatment." | ( Bi, Y; Chen, J; Xiea, K; Zeng, T; Zhao, X; Zhong, Z, 2013) |
| "In conclusion, the pulmonary fibrosis induced by silica in rats was significantly reduced with the therapeutic treatment of BMP-7." | ( Gao, A; Niu, P; Tian, L; Wang, Y; Yang, G; Zhu, Z, 2013) |
| "Administration of TAE226 ameliorated the pulmonary fibrosis induced by bleomycin in mice even when used late in the treatment." | ( Aono, Y; Azuma, M; Izumi, K; Kinoshita, K; Kishi, J; Kishi, M; Makino, H; Nishioka, Y; Okazaki, H; Sone, S; Takezaki, A; Uehara, H, 2013) |
| "Idiopathic pulmonary fibrosis (IPF) is the pathology with the highest degree of fibrosis and is of unknown etiology and burdened by lack of effective treatments in humans." | ( Cabiati, M; Del Ry, S; Della Latta, V; Morales, MA; Rocchiccioli, S, 2013) |
| "Treatment of wild-type mice with the pulmonary fibrosis-inducer bleomycin reduced the expression of Cav-2 and its phosphorylation at tyrosine 19." | ( de Almeida, CJ; Del Galdo, F; Jasmin, JF; Lisanti, MP, 2013) |
| "Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive interstitial lung disease with unknown etiology and undefined treatment modality." | ( Li, Y; Liang, C; Yang, W; Zhang, L, 2014) |
| "PTU treatment prevented both dermal and pulmonary fibrosis." | ( Altavilla, D; Atteritano, M; Bagnato, G; Bitto, A; Cinquegrani, M; Irrera, N; Pizzino, G; Roberts, W; Saitta, A; Sangari, D; Squadrito, F, 2013) |
| "The molecular pathogenesis of pulmonary fibrosis is not fully understood and the only effective treatment available is lung transplantation." | ( Choi, EY; Kang, YY; Kim, DY; Lee, SH, 2014) |
| "Idiopathic pulmonary fibrosis (IPF) is a progressive fibro-proliferative disorder refractory to current therapy commonly complicated by the development of pulmonary hypertension (PH); the associated morbidity and mortality are substantial." | ( Baliga, RS; Chambers, RC; Hobbs, AJ; MacAllister, RJ; Scotton, CJ; Trinder, SL, 2014) |
| "Idiopathic pulmonary fibrosis is a progressive fatal lung disease characterized by excessive collagen deposition, with no effective treatments." | ( Chilakapati, DR; Chilakapati, SR; Manikonda, PK; Serasanambati, M; Watson, RR, 2014) |
| "Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal disease, thought to be largely transforming growth factor β (TGFβ) driven, for which there is no effective therapy." | ( Lakshmi, SP; Reddy, AT; Reddy, RC; Zhang, Y, 2014) |
| "Administration of fasudil can attenuate pulmonary fibrosis both in vivo and in vitro." | ( Huang, H; Jiang, C; Liu, J; Wang, Y; Xu, Z; Zhao, Y, 2014) |
| "In rats treated with artesunate, pulmonary fibrosis induced by bleomycin was significantly reduced." | ( Huang, G; Jin, J; Wang, C; Xuan, X; Yao, W, 2015) |
| "IL-27 treatment may alleviate pulmonary fibrosis and increase the survival of mice." | ( Ai, L; Chai, Y; Dong, Z; Lei, W; Li, C; Li, Y; Lu, X; Tai, W; Yang, Y; Zhang, T, 2015) |
| "Radiation-induced pulmonary fibrosis (RIPF) is a late side effect of thoracic radiotherapy." | ( Cho, J; Choi, SH; Hong, ZY; Jang, J; Ji, YH; Kim, KH; Lee, CY; Lee, HJ; Lee, YJ; Lee, YS; Nam, JK; Park, S; Yoo, RJ, 2015) |
| "After treatment with HCPT, the degree of pulmonary fibrosis and the expression of TIMP-1 and type I collagen decreased in all treatment groups." | ( Hu, GX; Peng, YZ; Yao, ST; Zeng, LH; Zheng, J, 2015) |
| "Idiopathic and DC-associated pulmonary fibrosis are progressive and fatal disorders without known treatment." | ( Ciccolini, A; Dror, Y; Zlateska, B, 2015) |
| "Radiation-induced pulmonary fibrosis (RIF) is a severe complication of thoracic radiotherapy that limits its dose, intensity, and duration." | ( Aydogan, B; Berdyshev, EV; Bronova, I; Erdelyi, K; Makriyannis, A; Pacher, P; Smith, B; Vemuri, K; Weichselbaum, RR, 2015) |
| "Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal lung disease for which, thus far, there are no effective treatments." | ( Cao, ZD; Li, JX; Shen, Q; Xiao, N; Zhou, XM, 2016) |
| "Radiation-induced pulmonary fibrosis is a severe side effect of thoracic irradiation, but its pathogenesis remains poorly understood and no effective treatment is available." | ( Blackburn, MR; Cappuccini, F; Chen, NY; de Leve, S; Eldh, T; Fischer, U; Gau, E; Jendrossek, V; Karmouty-Quintana, H; Kasper, M; Klein, D; Meyer, AV; Ritchey, JW; Stuschke, M; Thompson, LF; Westendorf, AM; Wirsdörfer, F, 2016) |
| "IR-induced pulmonary fibrosis is one of the most severe late complications of radiotherapy for lung cancer." | ( Chen, C; Han, D; Hong, J; Ma, J; Okunieff, P; Yang, S; Zhang, L; Zhang, M; Zhang, SB; Zhang, Z, 2016) |
| "Idiopathic pulmonary fibrosis (IPF), one of the clinical common diseases, shares similar pathogenesis with ancient disease "Feibi" in Chinese medicine, Renshen pingfei decoction (RPFS), a classical prescription, was commonly used in treating Feibi." | ( Chen, F; Fan, XS; Wang, PL; Yu, JH; Zhu, Y; Zhu, ZH, 2016) |
| "Idiopathic pulmonary fibrosis (IPF) is a progressive, debilitating disease for which two medications, pirfenidone and nintedanib, have only recently been approved for treatment." | ( Bacon, KB; Boehme, SA; DiTirro, DN; Franz-Bacon, K; Ly, TW, 2016) |
| "Idiopathic pulmonary fibrosis (IPF) is a lethal human disease with short survival time and few treatment options." | ( Bian, H; Bu, X; Lai, X; Li, D; Su, J; Yao, L; Yu, J; Zhang, P; Zhang, S; Zhao, H; Zhu, C, 2016) |
| "Idiopathic pulmonary fibrosis (IPF) is a lethal lung disease with few treatment options and poor prognosis." | ( Cheng, W; Guan, R; Guo, Y; Jiang, L; Shen, L; Song, N; Wang, X; Yan, X; Zhao, X, 2016) |
| "After establishment of pulmonary fibrosis models by intratracheal administration with bleomycin A5, rats in control group, miR-21 agomir group and miR-21 antagomir group were injected at caudal vein with normal saline, miR21 agomir and miR21 antagomir, respectively." | ( He, J; Huang, M; Liu, L; Qian, H; Wang, Z; Yi, G; Yin, H, 2016) |
| "Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive disease of increasing prevalence marked by poor prognosis and limited treatment options." | ( Bacci, B; Bradding, P; Jaffar, J; Kimpton, WG; Koumoundouros, E; Nowell, CJ; Organ, L; Roach, KM; Samuel, CS; Snibson, KJ; Westall, G, 2017) |
| "In conclusion, the pulmonary fibrosis induced by silica in rats was significantly reduced by treatment with BMP-7-BMSCs and BMSCs." | ( An, G; Guo, C; Li, X; Lian, X; Liang, D; Niu, P; Tian, L; Wang, Y; Zhu, Z, 2017) |
| "Treatment with GNF6231 also reduced pulmonary fibrosis associated with murine cGvHD." | ( Althage, A; Beyer, C; Chen, CW; Cole, SH; Distler, JH; Gergely, P; Harris, JL; Hsieh, MH; Li, C; Liu, J; Maier, C; Meeusen, S; Ng, N; Pan, S; Schett, G; Seidel, HM; Svensson, EC; Trinh-Minh, T; Xu, X, 2017) |
| "The treatment options for pulmonary fibrosis are very limited." | ( Cao, J; Tao, L; Wei, W; Xie, H; Zhang, C; Zhang, M, 2017) |
| "Mice in pulmonary fibrosis model group were administered 5." | ( Chen, JY; Chen, Q; Dong, J; Nie, J; Shuai, W; Wang, H; Wang, YC; Xia, JM; Zhu, JX, 2017) |
| "BALB/C mice model of pulmonary fibrosis induced by an intratracheal instillation of BLM was adopted, and then was intraperitoneally injected with Thal (10, 20, 50 mg/kg) daily for 8 days, while the control and BLM-treated mouse groups were injected with a saline solution." | ( Chen, M; Dong, X; Fan, Q; Li, M; Li, X; Wei, W, 2017) |
| "BLM-induced lung inflammation and pulmonary fibrosis were significantly alleviated by GLP-1 treatment in mice, possibly through inactivation of NF-κB." | ( Chen, HT; Chen, ZH; Gou, S; Liu, M, 2017) |
| "Radiation-induced pulmonary fibrosis is a severe complication of patients treated with thoracic irradiation." | ( Chu, SG; Doyle-Eisele, M; El-Chemaly, S; Liu, X; McDonald, J; Patino-Jaramillo, NG; Perrella, MA; Rosas, IO; Tsoyi, K; Villalba, J; Wilder, J, 2018) |
| "Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal disease with no effective treatment." | ( Jeong, SH; Kim, DY; Kim, YJ; Kyung, SY; Park, JW; Son, ES; Yoon, JY, 2018) |
| "Astilbin ameliorates pulmonary fibrosis via blockade of Hedgehog signaling pathway and has potential therapeutic value for lung fibrosis treatment." | ( Liu, H; Lv, C; Song, C; Song, X; Wang, Y; Zhang, J, 2018) |
| "Administration of bleomycin caused pulmonary fibrosis in rats as evidenced by characteristic structural changes in histopathology, increased inflammatory cells in bronchoalveolar lavage fluid, elevated lipid peroxidation marker, depleted endogenous antioxidants and increased inflammatory mediators (TNF-α, IL-6)." | ( Arava, S; Arya, DS; Bhatia, J; Gamad, N; Malik, S; Suchal, K; Tomar, A; Vasisht, S, 2018) |
| "We conclude that FGF21 inhibits pulmonary fibrosis through activating Nrf-2 pathway, subsequently suppressing oxidative stress, inhibiting ECM deposition and pulmonary fibrogenesis, suggesting that FGF21 has potential as therapeutic agent for treatment of pulmonary fibrosis." | ( Huang, T; Li, D; Ren, G; Wang, M; Wang, W; Wu, H; Yin, J; Yu, D; Zhang, S; Zhang, T; Zhang, Y, 2018) |
| "Mice with bleomycin (BLM)-induced pulmonary fibrosis were treated with different doses of intragastric PTL, and pathological changes were evaluated using Hematoxylin-eosin (H&E) staining and immunohistochemical analysis." | ( Gao, JJ; Li, XH; Liu, HJ; Qin, Y; Xiao, T; Yang, JH; Zhou, HG, 2018) |
| "Three patients with HPS pulmonary fibrosis treated with open-label pirfenidone and twenty-one historical controls randomized to placebo were studied at a single center." | ( Akal, O; Akal, T; Barbu, A; Gahl, WA; Gochuico, BR; Introne, WJ; McGowan, MP; Merideth, MA; O'Brien, KJ; Seward, SL, 2018) |
| "An animal model of pulmonary fibrosis was established by administering an intratracheal injection of 5 mg/kg BLM to C57BL/6 mice." | ( Bai, Y; Fu, Q; Li, M; Liu, Y; Wen, X; Zheng, Y, 2018) |
| "To induce a pulmonary fibrosis mouse model, silica suspension and the miR-542-5p agomir were administered to mice by intratracheal instillation and tail vein injection." | ( Han, L; Ji, X; Li, P; Li, Y; Liu, Y; Ni, C; Pan, H; Xu, Q; Xu, T; Yao, W; Yuan, J, 2018) |
| "In a mouse model of bleomycin-induced pulmonary fibrosis, TAS-115 significantly inhibited the development of pulmonary fibrosis and the collagen deposition in bleomycin-treated lungs." | ( Goto, H; Homma, S; Kagawa, K; Kawano, H; Koyama, K; Morizumi, S; Nishimura, H; Nishioka, Y; Ogawa, H; Sato, S; Toyoda, Y, 2019) |
| "Idiopathic pulmonary fibrosis (IPF) is a chronic and deadly disease with a poor prognosis and few treatment options." | ( Assassi, S; Blackburn, MR; Bruckner, BA; Chen, NY; Collum, S; Davies, J; Han, L; Huang, J; Jyothula, SS; Karmouty-Quintana, H; Ko, J; Li, L; Li, W; Luo, F; Masamha, CP; Mertens, TC; Molina, JG; Philip, K; Thandavarayan, RA; Volcik, KA; Wagner, EJ; Weng, T; Wilson, C; Xia, Z; Xiang, Y, 2019) |
| "Radiation-induced pulmonary fibrosis (RTPF) is a progressive, serious condition in many subjects treated for thoracic malignancies or after accidental nuclear exposure." | ( Birukova, A; Cuttitta, F; Heck, K; Komforti, MK; Rouse, D; Soderblom, E; Sunday, ME; Tighe, RM; Toomey, CB; Vidas, J; Young, K; Zhou, S, 2019) |
| "Radiation-induced pulmonary fibrosis (RIPF) is a severe complication in patients treated with thoracic irradiation." | ( Cen, Y; Chen, X; Liu, T; Liu, Y; Pan, X; Yang, Q; Zhang, H; Zhang, P; Zhang, X, 2019) |
| "Silica-induced pulmonary fibrosis is a kind of worldwide occupational disease, and there is no effective treatment at present." | ( Ji, X; Li, P; Li, Y; Liu, Y; Ni, C; Pan, H; Xu, Q; Yao, W; Yuan, J, 2019) |
| "Idiopathic pulmonary fibrosis is characterized by loss of lung epithelial cells and inexorable progression of fibrosis with no effective and approved treatments." | ( Chen, M; Dong, M; Gao, Y; Han, L; Jin, F; Li, W; Lin, H; Shi, Y; Zhou, Y; Zuo, W, 2019) |
| "Other than idiopathic pulmonary fibrosis (IPF), there are no approved drugs for fibrosing ILDs and a poor evidence base to support current treatments." | ( Distler, JHW; Kolb, M; Maher, TM; Redente, EF; Riches, DWH; Schlenker-Herceg, R; Stowasser, S; Wollin, L, 2019) |
| "Idiopathic pulmonary fibrosis (IPF), a chronic, progressive and irreversible disease, needs long-term treatment." | ( Chai, X; Zhou, Y, 2020) |
| "SO₂ treatment significantly improves pulmonary fibrosis and pulmonary arterial remodeling." | ( Cui, H; Du, JB; Wang, XB, 2019) |
| "Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease with limited treatment options." | ( Arslanbas, E; Ekici, M; Gungor, H; Kara, H; Onder Karayigit, M; Turgut, NH, 2020) |
| "Idiopathic pulmonary fibrosis is a progressive-fibrosing lung disease with high mortality and limited therapy, which characterized by myofibroblasts proliferation and extracellular matrix deposition." | ( Bi, Z; Deng, R; Gao, S; Li, H; Li, S; Li, X; Liang, L; Lin, J; Liu, M; Luan, J; Ma, L; Miao, Y; Wang, M; Wang, Y; Yang, C; Yu, H; Zhou, H, 2020) |
| "BLM administration caused pulmonary fibrosis as evidenced by increased levels of inflammatory mediators (TGF-β1, TNF-α, IL-β1 and NF-κβ) in serum (P < ." | ( El Kiki, SM; Hasan, HF; Mansour, HH; Omran, MM, 2020) |
| "Radiation-induced pulmonary fibrosis (RIPF) is a long-term side effect of thoracic radiation therapy." | ( Cho, J; Choi, SH; Han, SC; Kim, AR; Kim, J; Kim, JH; Lee, HJ; Lee, YJ; Nam, JK; Park, S, 2021) |
| "Radiation-induced pulmonary fibrosis (RIPF) is a common complication during thoracic radiotherapy, but there are few effective treatments." | ( Chen, L; Han, S; Huang, Y; Jiang, Z; Leng, Y; Liao, F; Luo, M; Shen, G; Shi, C; Wang, Q; Wang, Y; Wang, Z; Wu, J; Zhang, A; Zhang, C; Zheng, J, 2021) |
| "However, pulmonary fibrosis therapy in the clinic has been limited by poor selectivity and inefficiency of drug delivery to fibroblasts." | ( Chen, Y; Fan, M; Gao, F; Huang, D; Li, B; Sun, L; Xu, R, 2021) |
| "Asthma-induced pulmonary fibrosis (PF) is an important public health concern that has few treatment options given its poorly understood etiology; however, the epithelial to mesenchymal transition (EMT) of pulmonary epithelial cells has been implicated to play an important role in inducing PF." | ( Gao, H; Gu, Y; Liu, P; Wang, J; Wang, Y; Zeng, H; Zhang, H; Zhang, M; Zhang, X; Zhao, L, 2021) |
| "Efficient therapy of idiopathic pulmonary fibrosis (IPF) is still a major challenge." | ( Fan, G; Gao, S; Qiao, Y; Sang, X; Shao, R; Wang, Y; Xue, Z; Yang, J; Zhao, F; Zhu, Y, 2021) |
| "Here, we found that the degree of pulmonary fibrosis induced by intragastric administration of PQ in congenital immunodeficiency BALB/C (nu/nu) nude (T lymphocyte loss) mice was lower than that in normal mice." | ( Dai, Z; Ding, Y; Hu, Y; Hua, H; Li, J; Li, Q; Li, T; Qian, C; Sun, H; Wang, J; Yang, X; Zhang, W, 2021) |
| "Both acute lung injury and pulmonary fibrosis have high mortality rates and few effective treatments." | ( Cui, Y; Gu, J; Huang, H; Li, S; Li, X; Liang, J; Liu, R; Ma, L; Wei, Y; Yang, C; Zhou, H, 2021) |
| "Subsequent to sacrificing of rats, pulmonary fibrosis was observed in rats treated with bleomycin, but administration of TEAR attenuated lung fibrosis, as evidenced by the improved lung histopathological damage and decreased weight loss and lung index." | ( Ding, DL; Liu, LM; Liu, Y; Ni, JZ; Nian, SH; Shen, XB; Wang, W; Yu, LZ, 2022) |
| "We prepared BLM induced pulmonary fibrosis model by administering BLM at a dose of 2 mg/ kg bodyweight." | ( Barki, RR; Bhandary, YP; Fathimath Muneesa, M; Shaikh, SB, 2022) |
| "The results indicated that the degree of pulmonary fibrosis and proteinosis in the NAC‑treated group was improved compared with that in the Nano-ITO-induced PAP model group." | ( Guan, Y; Li, G; Liu, N; Ma, Z; Wang, R; Yao, S; Zhao, L, 2022) |
| "In conclusion, Emodin could attenuate pulmonary fibrosis and EMT by regulating the c-MYC/miR-182-5p/ZEB2 axis, which might provide evidence for the application of Emodin in the treatment of pulmonary fibrosis." | ( Fan, L; Jiang, G; Ni, K; Tong, W; Yang, J, 2023) |
| "In conclusion, Emodin could attenuate pulmonary fibrosis and EMT by regulating the c-MYC/miR-182-5p/ZEB2 axis, which might provide evidence for the application of Emodin in the treatment of pulmonary fibrosis." | ( Fan, L; Jiang, G; Ni, K; Tong, W; Yang, J, 2023) |
| "In conclusion, Emodin could attenuate pulmonary fibrosis and EMT by regulating the c-MYC/miR-182-5p/ZEB2 axis, which might provide evidence for the application of Emodin in the treatment of pulmonary fibrosis." | ( Fan, L; Jiang, G; Ni, K; Tong, W; Yang, J, 2023) |
| "Nintedanib is an effective treatment for pulmonary fibrosis (PF), but the exact mechanism by which this agent works to delay the progression of PF remains unclear." | ( Cheng, Y; Pan, L; Tang, B; Wu, X; Yang, W; Zhang, M; Zhang, Y; Zhu, H, 2022) |
| "Nintedanib is an effective treatment for pulmonary fibrosis (PF), but the exact mechanism by which this agent works to delay the progression of PF remains unclear." | ( Cheng, Y; Pan, L; Tang, B; Wu, X; Yang, W; Zhang, M; Zhang, Y; Zhu, H, 2022) |
| "In this study, we report a case of pulmonary fibrosis after paraquat poisoning in a patient who underwent a lung transplant procedure after preoperative administration of corticosteroids and immunosuppressive agents and continuous noninvasive ventilation support therapy." | ( Li, N; Li, S; Song, S; Wu, Y, 2022) |
| "Treatment of pulmonary fibrosis caused by paraquat (PQ) poisoning remains problematic." | ( Chen, J; Cheng, B; Jian, X; Li, C, 2023) |
| "Therapeutic regimens for pulmonary fibrosis have shown limited benefits, hence justifying the efforts to evaluate the outcome of alternative treatments." | ( Araújo-Silva, CA; Benjamim, CF; Blanco, PJ; Bulant, CA; Canetti, C; Fraga-Junior, VS; Guilherme, RF; Lemos, FS; Magalhães, NS; Moraes, JA; Nogueira, TO; Pecli, C; Scharfstein, J; Serra, R; Silva, JBNF; Svensjö, E; Waclawiack, I, 2023) |
| "Although pulmonary fibrosis secondary to COVID-19 infection is uncommon, it can lead to problems if not treated effectively in the early period." | ( Akgün, M; Alper, F; Araz, Ö; Çil, G; Kerget, B, 2023) |
| "Radiation-induced pulmonary fibrosis (RIPF), one type of pulmonary interstitial diseases, is frequently observed following radiation therapy for chest cancer or accidental radiation exposure." | ( Chen, Y; Fu, S; Hao, Y; Li, J; Li, W; Li, Y; Li, Z; Liu, S; Qiao, L; Ran, Y; Shen, L; Zhang, J, 2023) |
| "An in vitro model of pulmonary fibrosis was established by treating NIH-3T3 cells with transforming growth factor-β1 (TGF-β1)." | ( Deng, L; Dong, J; Du, W; Hu, L; Li, S; Ouyang, B; Shi, H; Wei, Y; Xie, C; Yang, F, 2023) |
| "Idiopathic pulmonary fibrosis (IPF) is a progressive and ultimately fatal interstitial lung disease with poor prognosis and limited treatment options." | ( Chang, YF; Cheng, HP; Feng, DD; Fu, JF; Gao, LH; Huang, P; Huang, YH; Li, C; Li, XH; Liang, XY; Liu, W; Luo, ZQ; Qiu, YJ; Shao, M; Tang, SY; Zhang, YN; Zhou, Y, 2023) |
| "The incidence of pulmonary fibrosis is on the rise, and existing treatments have limited efficacy in improving patient survival." | ( Han, X; Wang, S; Wu, W, 2023) |
| "Idiopathic pulmonary fibrosis is a chronic and highly lethal lung disease that largely results from oxidative stress; however, effective antioxidant therapy by targeting oxidative stress pathogenesis is still lacking." | ( Chen, C; He, W; Huang, Y; Jia, H; Kotha, S; Liu, Q; Mao, X; Ren, Y; Tong, Y; Wang, L; Yuan, H; Zheng, Z, 2023) |